> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS Closing Opdivo Brain Tumor Program
- URL: https://www.fdaweb.com/bms-closing-opdivo-brain-tumor-program/
- Published: 2021-01-04T12:00:00.000Z
- Updated: 2026-09-14T16:41:18.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148346

Bristol-Myers Squibb is shutting down its Opdivo (nivolumab) program to use the immuno-onology drug in treating newly-diagnosed brain cancer patients. *Endpoints News* [reports](https://endpts.com/after-multiple-setbacks-and-os-flop-bristol-myers-scuttles-opdivo-program-for-newly-diagnosed-brain-tumor-patients/?ref=fdaweb.com) that Opdivo plus standard-of-care temozolomide (Merck’s Temodar) plus radiation performed no better than placebo in extending overall survival in patients with newly-diagnosed MGMT-positive glioblastoma multiforme who previously had their tumor surgically removed.

The report says an independent data monitoring committee had told BMS its Phase 3 Checkpoint-548 study would not meet the primary endpoint due to a high number of deaths in the overall patient pool and a subset of patients with no baseline corticosteroid use.